Mary Lou Smith and colleagues at the Research Advocacy Network recently explored how well patients with early-stage breast cancer understand risk of recurrence
The ethical imperative is that we must not treat the patient as a mere subject but as a participant partner, who therefore has rights to information about the trial to which they contributed